[1] Cheung AC, Larusso NF, Gores GJ, et al. Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis. Semin Liver Dis, 2017, 37(2): 159-174. [2] Park JW, Kim JH, Kim SE, et al. Primary biliary cholangitis and primary sclerosing cholangitis: current knowledge of pathogenesis and therapeutics. Biomedicines, 2022, 10(6)633-636. [3] Lyu T, Chen S, Li M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis. J Gastroenterol Hepatol, 2021, 36(6): 1423-1434. [4] 尤红, 段维佳, 李淑香, 等. 原发性胆汁性胆管炎的诊断和治疗指南(2021年). 临床肝胆病杂志, 2022, 38(1): 35-41. [5] You H, Ma X, Efe C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int, 2022, 16(1): 1-23. [6] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med, 2001, 344(7): 495-500. [7] Yamashita Y, Umemura T, Kimura T, et al. Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis. JHEP Rep, 2023, 5(4): 100662. [8] Tu Z, Wang Y, Wang Y, et al. TR score: a noninvasive model to predict histological stages in patients with primary biliary cholangitis. Front Immunol, 2023, 14:1152294. [9] Ludwig J, Dickson ER, Mcdonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol, 1978, 379(2): 103-112. [10] Trivella J, John BV, Levy C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment. Hepatol Commun, 2023, 7(6):325-328. [11] Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the american association for the study of liver diseases. Hepatology, 2019, 69(1): 394-419. [12] Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology, 2008, 134(4): 960-974. [13] 瞬时弹性成像技术(TE)临床应用专家共识(2015年). 中国肝脏病杂志(电子版), 2015, 7(2): 12-18. [14] Gómez-Dominguez E, Mendoza J, García-Buey L, et al. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther, 2008, 27(5): 441-447. [15] Corpechot C. Utility of noninvasive markers of fibrosis in cholestatic liver diseases. Clin Liver Dis, 2016, 20(1): 143-158. [16] Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep, 2020, 2(2): 100067. [17] Cristoferi L, Calvaruso V, Overi D, et al. Accuracy of transient elastography in assessing fibrosis at diagnosis in naïve patients with primary biliary cholangitis: a dual cut-off approach. Hepatology, 2021, 74(3): 1496-1508. [18] Islam S, Antonsson L, Westin J, et al. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol, 2005, 40(7): 867-872. [19] Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 2003, 38(2): 518-526. [20] Okdemir S, Cakmak E. A novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B. Ann Hepatol, 2022, 27(1): 100544. |